Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages
in developing bacterial consortia that are designed to functionally interact
with host cells and tissues to treat disease. The company's lead product
candidate is the SER-109, an oral microbiome therapeutic candidate that has
completed Phase III clinical trial for the treatment of clostridium difficile
infection (CDI). It is also developing SER-155, a cultivated bacteria
microbiome drug, which is Phase Ib clinical trial to reduce incidences of
gastrointestinal infections, bloodstream infections, and graft versus host
diseases in immunocompromised patients receiving allogeneic hematopoietic stem
cell transplantation and solid organ transplants. In addition, the company
engages in the development of SER-287 and SER-301 that are in Phase Ib to treat
ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262
to treat Clostridioides difficile infection. It has license and collaboration
agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The
company was formerly known as Seres Health, Inc. and changed its name to Seres
Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in
2010 and is headquartered in Cambridge, Massachusetts.
